PMID- 31569090
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20191114
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 64
IP  - 2
DP  - 2019
TI  - Effectiveness and Safety of Combination Therapy of Transarterial 
      Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the 
      Chinese Population: A Meta-Analysis.
PG  - 94-104
LID - 10.1159/000502510 [doi]
AB  - BACKGROUND: The combination of transarterial chemoembolization (TACE) and 
      apatinib has been used in the treatment of intermediate or advanced 
      hepatocellular carcinoma (HCC). However, its effectiveness and safety are also 
      argued. METHODS: Eligible studies were collected from a computer search of 
      literatures published from the database establishment to May 2019 in PubMed, Web 
      of Science, EMBASE, Ovid, the Cochrane Library, Wanfang Database, China National 
      Knowledge Infrastructure, and China Biology Medicine Disc. The objective response 
      rate (ORR), the disease control rate (DCR), survival rate (SR), and the 
      incidences of treatment-related adverse effects (AEs) were collected as the 
      relevant outcomes. Data were analyzed through fixed/random effects of 
      meta-analysis models with RevMan 5.3 software. RESULTS: Eight randomized 
      controlled clinical trials comprising 528 patients and 4 cohort studies 
      comprising 226 patients were eventually included. Compared to the control group 
      treated with TACE solely, combination therapy group, in which intermediate or 
      advanced HCC patients were treated with TACE and apatinib, significantly enhanced 
      ORR (relative risk [RR] 2.06, 95% CI 1.63-2.61, p < 0.001), DCR (RR 1.65, 95% CI 
      1.24-2.20, p < 0.001), and whole SRs of 6-month (RR 1.52, 95% CI 1.08-2.14, p = 
      0.02), 1-year (RR 1.52, 95% CI 1.25-1.84, p < 0.001), and 2-year (RR 1.84, 95% CI 
      1.34-2.54, p < 0.001). The incidence of hand foot syndrome, proteinuria, 
      hypertension, and diarrhea was significantly increased in the combination therapy 
      group compared with the control group (p < 0.05), and the incidence of nausea and 
      vomiting, fever, and myelosuppression, respectively, was similar in 2 groups (p > 
      0.05). CONCLUSIONS: The combination therapy of TACE and apatinib can enhance the 
      clinical effectiveness better than TACE solely in patients with intermediate or 
      advanced HCC, while increase in the AEs is usually tolerable.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Wei, Yan
AU  - Wei Y
AD  - Department of Gastroenterology, Tangdu Hospital of the Fourth Military Medical 
      University, Xi'an, China.
AD  - Department of Outpatient, 986th Military Hospital, Xi'an, China.
FAU - Liu, Jianjun
AU  - Liu J
AD  - Department of Outpatient, 986th Military Hospital, Xi'an, China.
FAU - Yan, Min
AU  - Yan M
AD  - Department of Epidemiology, School of Public Health, The Fourth Military Medical 
      University, Xi'an, China.
FAU - Zhao, Shuguang
AU  - Zhao S
AD  - Department of Gastroenterology, Tangdu Hospital of the Fourth Military Medical 
      University, Xi'an, China.
FAU - Long, Yong
AU  - Long Y
AD  - Department of Epidemiology, School of Public Health, The Fourth Military Medical 
      University, Xi'an, China.
FAU - Zhang, Weilu
AU  - Zhang W
AD  - Department of Epidemiology, School of Public Health, The Fourth Military Medical 
      University, Xi'an, China, zhangweilu@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20190930
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Carcinoma, Hepatocellular/mortality/*therapy
MH  - Chemoembolization, Therapeutic
MH  - Humans
MH  - Liver Neoplasms/mortality/*therapy
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - Risk
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Apatinib
OT  - Hepatocellular carcinoma
OT  - Meta-analysis
OT  - Therapy
OT  - Transarterial chemoembolization
EDAT- 2019/10/01 06:00
MHDA- 2019/11/15 06:00
CRDT- 2019/10/01 06:00
PHST- 2019/06/21 00:00 [received]
PHST- 2019/08/05 00:00 [accepted]
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2019/10/01 06:00 [entrez]
AID - 000502510 [pii]
AID - 10.1159/000502510 [doi]
PST - ppublish
SO  - Chemotherapy. 2019;64(2):94-104. doi: 10.1159/000502510. Epub 2019 Sep 30.